Clinical Trials
Clinical Trials can offer benefits to patients, as well as the chance to impact future esophageal cancer treatment. If you would like more information about Esophageal Cancer Clinical Trials offered at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, please contact 410-933-5420.
Current trial listing:
Metastatic – 1st Line
J20131 – Efficacy and Safety of Lenvatinib plus Pembrolizumab plus Chemotherapy in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma Compared with Standard of Care Therapy
NCT04662710
J2169 – Efficacy and Safety of Pembrolizumab plus Lenvatinib plus Chemotherapy in Patients with Metastatic Esophageal Carcinoma Compared with Standard of Care
NCT04949256
Metastatic – 2nd line and beyond
J1884 – REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-Oncology) – Nivolumab or Nivolumab/Relatimab after Targeted Systematic Radiation in Participants with Advanced Esophagogastric Cancer
NCT03610711
J19135 – Phase 2 Study of Paclitaxel, Pembrolizumab, and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
NCT04209686
J2154 – A Phase 1 Safety Study of SEA-TGT (SGN-TGT) in Participants with Advanced Malignancies
NCT04254107
J21111 – Phase I/II Study of Abemaciclib plus Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas
NCT04921904
HER2+
J2084 – A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antituor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596
J20120 – A Phase I/II, First-In-Human, Multi-Part, OpenLabel, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications (DF1001-001)
NCT04143711